AlloDerm (LifeCell, Branchburg, NJ) is gaining acceptance in tissue expander/implant (TE/I) breast reconstruction. Anecdotal evidence suggests its use limits postoperative musculoskeletal morbidity and allows injection of greater initial fill-volumes and rapid postoperative expansion. The objective of this study was to evaluate AlloDerm's impact on expansion rates in immediate TE/I reconstruction. A matched, retrospective cohort study was performed. Medical records of patients who underwent immediate TE/I reconstruction from 2004 to 2005 were reviewed. Two cohorts were identified: (1) underwent TE/I reconstruction with AlloDerm, and (2) underwent standard TE/I reconstruction. Individuals were matched 1:1 on the basis of: expander size (+/-100 mL), history of irradiation, and indication for mastectomy. Cohorts were compared for intraoperative volume injected (mL), rate of postoperative expansion (mL/ injection), number of expansions, and time to completion of expansion (days). Incidence of complications was evaluated. Pairwise comparisons were performed using the Wilcoxon sign rank test and McNemar test. Ninety immediate TE/I reconstructions were evaluated. Forty-five TE/I-AlloDerm reconstructions were matched to standard TE/I reconstructions. Intraoperatively, expanders in the AlloDerm and non-AlloDerm cohorts were filled to a mean volume of 223.8 and 201.1 mL (P = 0.180). Median number of expansions performed was 5 and 6 in the AlloDerm and non-AlloDerm cohorts (P = 0.117). There was no difference in the mean rate of postoperative tissue expansion (AlloDerm: 97 mL/injection versus non-AlloDerm: 95 mL/injection [P = 0.907]), nor in the incidence of complications (P = 0.289). Minor complications occurred in 13.1% of AlloDerm cases (cellulitis [n = 3], seroma [n = 3], hematoma [n = 1]. Although this study does not address AlloDerm's efficacy in decreasing morbidity or improving esthetic outcomes in TE/I reconstruction, it indicates that AlloDerm does not increase the rate of tissue expansion after immediate TE placement. It does not, however, appear to increase the risk of postoperative complications.

译文

AlloDerm (LifeCell,新泽西州布兰奇堡) 正在组织扩张器/植入物 (TE/I) 乳房重建中获得认可。轶事证据表明,其使用限制了术后肌肉骨骼的发病率,并允许注射更大的初始填充量和术后快速扩张。这项研究的目的是评估AlloDerm在即时TE/I重建中对膨胀率的影响。进行了一项匹配的回顾性队列研究。回顾了2004年2005年立即进行TE/I重建的患者的病历。确定了两个队列 :( 1) 用同种异体进行TE/I重建,(2) 进行标准TE/I重建。1:1根据以下因素对个体进行匹配: 扩张器大小 (/-100 mL),照射史和乳房切除术的适应症。比较队列的术中注射量 (mL),术后扩张率 (mL/注射),扩张次数和扩张完成时间 (天)。评估并发症的发生率。使用Wilcoxon符号秩检验和McNemar检验进行成对比较。对90例即时TE/I重建进行了评估。45种TE/I-同种异体重建与标准TE/I重建相匹配。术中,将同种异体和非同种异体队列中的扩张剂填充至平均体积为223.8和201.1 mL (P = 0.180)。在同种异体和非同种异体队列中进行的扩增的中位数为5和6 (P = 0.117)。术后组织扩张的平均速率 (同种异体: 97 mL/注射与非同种异体: 95 mL/注射 [P = 0.907]) 没有差异,并发症的发生率也没有差异 (P = 0.289)。13.1% 同种异体病例发生轻微并发症 (蜂窝织炎 [n = 3],血清肿 [n = 3],血肿 [n = 1]。尽管这项研究没有解决同种异体在TE/I重建中降低发病率或改善美学结果的功效,这表明AlloDerm不会增加立即放置TE后的组织扩张率。但是,它似乎不会增加术后并发症的风险。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录